Dementia Associated With Alzheimer's Disease - Pipeline Review - H1 2014





Published: March 2014 | Pages: 52 | Format: PDF

 Summary  

 Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2014’, provides an overview of the Dementia Associated With Alzheimer's Disease’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia Associated With Alzheimer's Disease and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

  •  The report provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Dementia Associated With Alzheimer's Disease and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Dementia Associated With Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Dementia Associated With Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 Reasons to buy 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for Dementia Associated With Alzheimer's Disease 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Table of Contents 

 Introduction 5 

 Global Markets Direct Report Coverage 5 

 Dementia Associated With Alzheimer's Disease Overview 6 

 Therapeutics Development 7 

 Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview 7 

 Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis 8 

 Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies 9 

 Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 11 

 Dementia Associated With Alzheimer's Disease - Pipeline Products Glance 12 

 Late Stage Products 12 

 Clinical Stage Products 13 

 Early Stage Products 14 

 Dementia Associated With Alzheimer's Disease - Products under Development by Companies 15 

 Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes 16 

 Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development 17 

 Kowa Company, Ltd. 17 

 MediPost Co., Ltd. 18 

 e-Therapeutics plc 19 

 Adamas Pharmaceuticals, Inc. 20 

 Chase Pharmaceuticals Corporation 21 

 Dementia Associated With Alzheimer's Disease - Therapeutics Assessment 22 

 Assessment by Monotherapy Products 22 

 Assessment by Combination Products 23 

 Assessment by Target 24 

 Assessment by Mechanism of Action 27 

 Assessment by Route of Administration 30 

 Assessment by Molecule Type 32 

 Drug Profiles 34 

 (memantine hydrochloride ER + donepezil hydrochloride) - Drug Profile 34 

 Product Description 34 

 Mechanism of Action 34 

 R&D Progress 34 

 K-828-AB - Drug Profile 35 

 Product Description 35 

 Mechanism of Action 35 

 R&D Progress 35 

 Neurostem - Drug Profile 36 

 Product Description 36 

 Mechanism of Action 36 

 R&D Progress 36 

 TAK-070 - Drug Profile 38 

 Product Description 38 

 Mechanism of Action 38 

 R&D Progress 38 

 ETX-6765 - Drug Profile 39 

 Product Description 39 

 Mechanism of Action 39 

 R&D Progress 39 

 CPC-001 - Drug Profile 40 

 Product Description 40 

 Mechanism of Action 40 

 R&D Progress 40 

 erlotinib hydrochloride - Drug Profile 41 

 Product Description 41 

 Mechanism of Action 41 

 R&D Progress 41 

 gefitinib - Drug Profile 42 

 Product Description 42 

 Mechanism of Action 42 

 R&D Progress 42 

 AVCRI-104P3 - Drug Profile 43 

 Product Description 43 

 Mechanism of Action 43 

 R&D Progress 43 

 Dementia Associated With Alzheimer's Disease - Recent Pipeline Updates 44 

 Dementia Associated With Alzheimer's Disease - Dormant Projects 45 

 Dementia Associated With Alzheimer's Disease - Discontinued Products 46 

 Dementia Associated With Alzheimer's Disease - Product Development Milestones 47 

 Featured News & Press Releases 47 

 Jan 31, 2014: Forest Laboratories Files Lawsuit Against Several Companies for Infringement of NAMENDA XR Patents 47 

 Jun 13, 2013: Forest Labs Announces US Availability Of New Once-daily Namenda XR 47 

 Oct 26, 2012: New Research Demonstrates Potential Of IRX4204 For Reduction Of Dementia In Animal Models Of Alzheimer's And Parkinson's Disease 48 

 May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda 48 

 Jun 03, 2011: IQWiG Recognizes Benefits Of Memantine 49 

 Appendix 51 

 Methodology 51 

 Coverage 51 

 Secondary Research 51 

 Primary Research 51 

 Expert Panel Validation 51 

 Contact Us 52 

 Disclaimer 52 

  

 List of Tables 

 Number of Products under Development for Dementia Associated With Alzheimer's Disease, H1 2014 7 

 Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H1 2014 8 

 Number of Products under Development by Companies, H1 2014 10 

 Number of Products under Investigation by Universities/Institutes, H1 2014 11 

 Comparative Analysis by Late Stage Development, H1 2014 12 

 Comparative Analysis by Clinical Stage Development, H1 2014 13 

 Comparative Analysis by Early Stage Development, H1 2014 14 

 Products under Development by Companies, H1 2014 15 

 Products under Investigation by Universities/Institutes, H1 2014 16 

 Dementia Associated With Alzheimer's Disease - Pipeline by Kowa Company, Ltd., H1 2014 17 

 Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H1 2014 18 

 Dementia Associated With Alzheimer's Disease - Pipeline by e-Therapeutics plc, H1 2014 19 

 Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H1 2014 20 

 Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H1 2014 21 

 Assessment by Monotherapy Products, H1 2014 22 

 Assessment by Combination Products, H1 2014 23 

 Number of Products by Stage and Target, H1 2014 26 

 Number of Products by Stage and Mechanism of Action, H1 2014 29 

 Number of Products by Stage and Route of Administration, H1 2014 31 

 Number of Products by Stage and Molecule Type, H1 2014 33 

 Dementia Associated With Alzheimer's Disease Therapeutics - Recent Pipeline Updates, H1 2014 44 

 Dementia Associated With Alzheimer's Disease - Dormant Projects, H1 2014 45 

 Dementia Associated With Alzheimer's Disease - Discontinued Products, H1 2014 46 

  

 List of Figures 

 Number of Products under Development for Dementia Associated With Alzheimer's Disease, H1 2014 7 

 Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H1 2014 8 

 Number of Products under Development by Companies, H1 2014 9 

 Number of Products under Investigation by Universities/Institutes, H1 2014 11 

 Comparative Analysis by Clinical Stage Development, H1 2014 13 

 Comparative Analysis by Early Stage Products, H1 2014 14 

 Assessment by Monotherapy Products, H1 2014 22 

 Number of Products by Top 10 Target, H1 2014 24 

 Number of Products by Stage and Top 10 Target, H1 2014 25 

 Number of Products by Top 10 Mechanism of Action, H1 2014 27 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28 

 Number of Products by Top 10 Route of Administration, H1 2014 30 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 31 

 Number of Products by Top 10 Molecule Type, H1 2014 32 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 33 

  

 Companies Mentioned 

 Kowa Company, Ltd. 

 MediPost Co., Ltd. 

 e-Therapeutics plc 

 Adamas Pharmaceuticals, Inc. 

 Chase Pharmaceuticals Corporation